Other Venetoclax-based Combination Regimens Being Evaluated in Multiple Myeloma

Treatment with maintenance daratumumab, with or without pomalidomide, led to a median PFS of 28.5 months in patients with relapsed multiple myeloma after undergoing salvage autologous hematopoietic stem cell transplantation.

Recent studies reported a potential reduction in stem cell yields in patients who were exposed to daratumumab prior to stem cell mobilization.

Interim findings from the phase 2 EMN19 study coupled with the phase 2 LYRA study findings suggest DaraVCD is another option for multiple myeloma with extramedullary disease.

At 2-year follow-up, patients with relapsed/refractory multiple myeloma treated with teclistamab achieved a median progression-free survival of 12.5 months with a median duration of response of 24 months.

In patients with relapsed/refractory multiple myeloma who were previously treated with lenalidomide, the combination of daratumumab, ixazomib, and dexamethasone led to improved overall response rates.

In the second article of this 2-part series, Douglas Sborov, MD, discusses the relevant data that shows the benefit of giving patients with relapsed/refractory multiple myeloma isatuximab as part of a triplet therapy.